USING KARNOFSKY PERFORMANCE STATUS (KPS) OF BONE MARROW TRANSPLANT (BMT) PATIENTS AT TIME OF TRANSPLANT AS A PREDICTOR OF OVERALL SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

2.50
Hdl Handle:
http://hdl.handle.net/10755/165096
Category:
Abstract
Type:
Presentation
Title:
USING KARNOFSKY PERFORMANCE STATUS (KPS) OF BONE MARROW TRANSPLANT (BMT) PATIENTS AT TIME OF TRANSPLANT AS A PREDICTOR OF OVERALL SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
Author(s):
Privitere, Lisa; Syta, Margaret
Author Details:
Lisa Privitere, RN OCN, Head Nurse, Roswell Park Cancer Institute, Buffalo, New York, USA, email: lisa.privitere@roswellpark.org, email: Margaret Syta, RN, NP
Abstract:
Refractory AML and MDS are difficult diseases to manage due to recurrent disease. We retrospectively reviewed 47 consecutive patients with AML (n=36) or MDS (n =11) who received a first related (n=23) or unrelated (n=24) Allogeneic BMT between 4/1/2003 and 3/31/2006 at Roswell Park Cancer Institute (RPCI) to compare outcomes by pre- BMT disease status. 16 patients had a KPS of 100% to 90% and 31 had a KPS of 80% or less. Examples of additional patient factors analyzed in addition to KPS relative to outcome were diagnosis, disease status conditioning regimen, HLA matching, graft versus host disease (GVHD) prophylaxis, viral infection, fungal infection, age, ejection fraction, select pulmonary function tests (PFTs). KPS was the only significant predictor of overall survival. The good of this project is to identify what factors other than cytoreducing the patient before hematopoetic stem cell transplant (HSCT) such as KPS, age and human leukocyte antigen (HLA) status affect outcome. Patients with a KPS<90% have been identified as high risk for poor outcome and are monitored more closely with a stringent assessment. Communications among the interdisciplinary team are prioritized for immediate response. We participated in a retrospective cohort study of 116 consecutive AML and MDS patients between 1/1/2003 and 7/1/2006. Of this patient population 47(41%) actually received an allo HSCT at our center. As a result of our findings our standard nursing orders have been revised to address the potential acuity of a patient with a low KPS to ensure early detection of status changes. We have also reduced the intensity of the conditioning regimens, using re-induction strategies that do not compromise KPS. That low KPS is a strong predictor of poor long-term disease free survival (LFS) and overall survival (OS).
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleUSING KARNOFSKY PERFORMANCE STATUS (KPS) OF BONE MARROW TRANSPLANT (BMT) PATIENTS AT TIME OF TRANSPLANT AS A PREDICTOR OF OVERALL SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)en_GB
dc.contributor.authorPrivitere, Lisaen_US
dc.contributor.authorSyta, Margareten_US
dc.author.detailsLisa Privitere, RN OCN, Head Nurse, Roswell Park Cancer Institute, Buffalo, New York, USA, email: lisa.privitere@roswellpark.org, email: Margaret Syta, RN, NPen_US
dc.identifier.urihttp://hdl.handle.net/10755/165096-
dc.description.abstractRefractory AML and MDS are difficult diseases to manage due to recurrent disease. We retrospectively reviewed 47 consecutive patients with AML (n=36) or MDS (n =11) who received a first related (n=23) or unrelated (n=24) Allogeneic BMT between 4/1/2003 and 3/31/2006 at Roswell Park Cancer Institute (RPCI) to compare outcomes by pre- BMT disease status. 16 patients had a KPS of 100% to 90% and 31 had a KPS of 80% or less. Examples of additional patient factors analyzed in addition to KPS relative to outcome were diagnosis, disease status conditioning regimen, HLA matching, graft versus host disease (GVHD) prophylaxis, viral infection, fungal infection, age, ejection fraction, select pulmonary function tests (PFTs). KPS was the only significant predictor of overall survival. The good of this project is to identify what factors other than cytoreducing the patient before hematopoetic stem cell transplant (HSCT) such as KPS, age and human leukocyte antigen (HLA) status affect outcome. Patients with a KPS&lt;90% have been identified as high risk for poor outcome and are monitored more closely with a stringent assessment. Communications among the interdisciplinary team are prioritized for immediate response. We participated in a retrospective cohort study of 116 consecutive AML and MDS patients between 1/1/2003 and 7/1/2006. Of this patient population 47(41%) actually received an allo HSCT at our center. As a result of our findings our standard nursing orders have been revised to address the potential acuity of a patient with a low KPS to ensure early detection of status changes. We have also reduced the intensity of the conditioning regimens, using re-induction strategies that do not compromise KPS. That low KPS is a strong predictor of poor long-term disease free survival (LFS) and overall survival (OS).en_GB
dc.date.available2011-10-27T12:12:27Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:12:27Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.